Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

OncoAlert Colloquium Day 3: Breast cancer

Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara...

OncoAlert Colloquium Day 3: Breast cancer ( Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara Tolaney, Dr Matteo Lambertini & Dr Icro Meattini )

OncoAlert Colloquium Day 2: Lung cancer and MASCC

Dr Stephen Liu, Dr Jack West, Dr Sanay Popat, Dr Jarushka Naidoo, Dr Percy Lee...

OncoAlert Colloquium Day 2: Lung cancer and MASCC ( Dr Stephen Liu, Dr Jack West, Dr Sanay Popat, Dr Jarushka Naidoo, Dr Percy Lee, Ms Jill Feldman, Ms Ivy Elkins, Dr Andrew Davies & Dr Joanne Bowen )

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology

Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean...

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology ( Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBride, Dr Ravindran Kanesvaran & Dr Nicolo Battisti )

Dihydropyrimidine dehydrogenase polymorphisms knocking on the door

Dr Mauro Daniel Donadio - AC Camargo Cancer Center, Sao Paulo, Brazil

Dihydropyrimidine dehydrogenase polymorphisms knocking on the door ( Dr Mauro Daniel Donadio - AC Camargo Cancer Center, Sao Paulo, Brazil )

Frontline treatment with single agent pembrolizumab followed by AVD...

Prof Pamela Allen - Emory University School of Medicine, Georgia, USA

Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma ( Prof Pamela Allen - Emory University School of Medicine, Georgia, USA )

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib +...

Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease ( Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA )

Efficacy and safety of selinexor in patients with myelofibrosis refractory or...

Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA

$Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors ( Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA )$

Significance of gut microbiota in patients receiving CAR T cell immunotherapy

Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA

Significance of gut microbiota in patients receiving CAR T cell immunotherapy ( Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA )

The RxPONDER trial and its impact on best clinical practice

Prof Christos Markopoulos and Prof Giuseppe Curigliano

The RxPONDER trial and its impact on best clinical practice ( Prof Christos Markopoulos and Prof Giuseppe Curigliano )

WHO and St. Jude Children’s research hospital to dramatically increase global...

Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer...

WHO and St. Jude Children’s research hospital to dramatically increase global access to childhood cancer medicine ( Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer Initiative )

More from ecancer